title: Apoptosis in cervical cancer after balloon-occluded arterial infusion of anticancer drugs.
abstract: BACKGROUND
  This study was designed to investigate the relationship between apoptosis and Bcl-2 and Bax expressions in uterine cervical cancer after balloon-occluded arterial infusion (BOAI).
  
  
  METHODS
  Twenty-four specimens were obtained before and after BOAI. The occurrence of apoptosis was examined with molecular biochemical techniques. The expressions of Bcl-2 and Bax proteins were investigated by immunohistochemical staining.
  
  
  RESULTS
  Labelling of DNA in situ indicated that apoptotic cells were sporadically seen before BOAI (6.1 +/- 1.9). Apoptotic cells apparently increased at 5 days (25.1 +/- 6.4) after BOAI The autoradiographic analysis revealed that the DNA-ladder was identified at 5 days after BOAI. Although Bcl-2 immuno-reactivity was faintly detected, the expression of Bax increased at 3 days (49.4 +/- 10.4%) after BOAI.
  
  
  CONCLUSIONS
  The results indicated that treatment with BOAI resulted in transient increases of apoptosis in cervical cancer in association with the increased expression of Bax.
authors.affiliation: Department of Obstetrics and Gynecology, Wakayama Medical University, Wakayama 641-0012, Japan. katsu@wakayama-med.ac.jp
authors.forename: Katsuji
authors.initials: K
authors.lastname: Kokawa
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Mabuchi
authors.forename: Kazuharu
authors.initials: K
authors.lastname: Tanaka
authors.forename: Shigetaka
authors.initials: S
authors.lastname: Yagi
authors.forename: Tomoko
authors.initials: T
authors.lastname: Utsunomiya
authors.forename: Nami
authors.initials: N
authors.lastname: Oba
authors.forename: Chie
authors.initials: C
authors.lastname: Yata
authors.forename: Naohiko
authors.initials: N
authors.lastname: Umesaki
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D002404:Catheterization; D002945:Cisplatin / Q000008:administration & dosage; D053938:DNA Fragmentation / Q000187:drug effects*; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007261:Infusions, Intra-Arterial; D008875:Middle Aged; D017663:Peplomycin / Q000008:administration & dosage; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000096:biosynthesis; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D051028:bcl-2-Associated X Protein / Q000096:biosynthesis
chemical_list: C494826:BAX protein, human; D019253:Proto-Oncogene Proteins c-bcl-2; D051028:bcl-2-Associated X Protein; D017663:Peplomycin; D004317:Doxorubicin; C027260:pirarubicin; D002945:Cisplatin